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Background: The most widely used maintenance treatment for opioid dependency is substitution with long-acting
oral opioids. Treatment with injectable diacetylmorphine provides an opportunity for patients to stabilize and
possibly transition to oral treatment, if clinically indicated. The aim of this study was to explore outcomes of
individuals that received injectable diacetylmorphine and voluntarily transitioned to oral methadone.
Design and methods: The North American Opiate Medication Initiative was a randomized controlled trial that
compared the effectiveness of injectable diacetylmorphine (or hydromorphone) to oral methadone for long-term
opioid-dependency. Treatment was provided for 12-months with an additional 3 months for transition and weaning.
Participants were followed until 24-months from randomization. Among the participants randomized to injectable
treatments, a sub-group voluntarily chose to transition to oral methadone (n = 16) during the treatment period. Illicit
heroin use and treatment retention were assessed at 24-months for those voluntarily and involuntarily transitioning
(n = 95) to oral methadone.
Results: At 24-months, the group that voluntarily transitioned to oral methadone had higher odds of treatment
retention (adjusted odds ratio = 5.55; 95% confidence interval [CI] = 1.11, 27.81; Chi-square = 4.33, df = 1, p-value = 0.037)
than the involuntary transition group. At 24-months, the adjusted mean difference in prior 30 days of illicit heroin
use for the voluntary, compared to the involuntary group was −5.58 (95% CI = −11.62, 0.47; t-value = −1.83, df = 97.4,
p-value = 0.070).
Conclusions: Although the results of this study were based on small groups of self-selected (i.e., non-randomized)
participants, our data underlines the critical importance of voluntary and patient-centered decision making. If we had
continued offering treatment with diacetylmorphine, those retained to injectable medication may have sustained the
achieved improvements in the first 12 months. Diversified opioid treatment should be available so patients and
physicians can flexibly choose the best treatment at the time.
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Dependency on heroin and other opioids is a chronic re-
lapsing disease and continues to be a major public health
concern. Individuals injecting street opioids are vulner-
able to blood borne diseases, overdoses, premature death
and involvement in criminal activities to sustain their
drug use [1-3]. Currently, the most widely used and
studied maintenance treatment for opioid dependency is
substitution with methadone [4]. Methadone mainten-
ance treatment (MMT) is effective at reducing the above
harms associated with illicit opioid use [5]. For those for
whom oral methadone is not effective, despite repeated
attempts in the past, studies in Europe and Canada have
demonstrated that medically supervised treatment with
injectable diacetylmorphine (DAM) is effective [6,7].
Supervised injectable DAM is associated with increased
retention in addiction treatment and decreased use of
illicit substances, involvement in criminal activity and
incarceration, and possibly reduced mortality [6,7]. Also,
this treatment model provides an opportunity for indi-
viduals using illicit opioids to connect and engage with
the addiction treatment system. Moreover, after starting
treatment with DAM, some patients may choose to
transfer to MMT. European studies suggest that among
those who stopped treatment with injectable diacetyl-
morphine, approximately 30% per year transitioned to
MMT [8,9]. The supervised model requires clinic visits
two to three times per day, which has been suggested it
could affect individuals’ psychosocial functioning [10].
Therefore, if clinically indicated and in consultation with
the patient, transitions to other forms of treatments, in
particular long acting oral opioids, might be a favourable
outcome. The present study sought to determine out-
comes of participants receiving injectable DAM in a
Canadian trial who voluntarily transitioned to oral
methadone during the study period compared to those
whose treatment was discontinued as the study ended.
Methods
Study design, setting, participants and procedures
The North American Opiate Medication Initiative (NAOMI)
study was a phase III, open-label randomized controlled
trial that compared the effectiveness of injectable diacetyl-
morphine to oral methadone for treatment-refractory
opioid-dependence. The study was conducted in Vancou-
ver and Montreal, Canada, between March 2005 and July
2008. Study results, methodology and patients’ profiles
have been published elsewhere [11-13]. Inclusion criteria
were opioid dependence [14]; daily opioid injection; at
least 5 years of opioid use; a minimum age of 25; a mini-
mum of two previous treatments for opioid dependence
including at least one attempt at MMT (in which 60 milli-
grams or more of methadone was received daily for at
least 30 days within a 40 day period); and no enrolment inMMT within the prior 6 months. Participants were ran-
domly assigned to receive oral methadone (n = 111),
injectable diacetylmorphine (n = 115) or injectable hydro-
morphone (n = 25) for a period of 12 months. At the end
of the 12-month study treatment period, participants’ still
receiving injectable medications had three months to tran-
sition to other treatments available in the community
(most likely oral methadone, as injectable medications
were not available post-trial). All participants provided
written informed consent. The trial received approval by
the ethics review boards in each study site.
Measures
Research evaluations were conducted at a separate re-
search office by a team not involved in participants' treat-
ment. This analysis presents data from the European
Addiction Severity Index (EuropASI) [15], Maudsley
Addiction Profile (MAP) [16] and EuroQol (EQ5D) [17],
administered prior to randomization and at 12 and 24-
months follow-up. A total of five participants withdrew
their consent in the methadone group and one in the in-
jectable diacetylmorphine group. The follow-up rates at 12
(end of treatment) and 24-months were 95.6% and 82.9%,
respectively. To be considered retained to treatment, a
participant must have been abstinent of opioids or con-
firmed to be receiving their study medication or any other
addiction treatment during at least 10 of the 14 days prior
to the 12-month assessment or 20 of the 30 days prior to
the 24-month assessment.
Statistical analyses
Data from participants randomized to either injectable
diacetylmorphine or hydromorphone were combined,
based on similar outcomes during the active treatment
study period [18]. These participants were then divided
into three groups: 1) ‘voluntary transition’ (n = 16) were
those who voluntarily stopped receiving injectable medica-
tions and transitioned to oral methadone before the
12 month time-point; 2) ‘involuntary transition’ (n = 95)
were those who were still receiving injectables at 12 months
but were discontinued and offered other treatments be-
cause their study period ended; and 3) ‘withdrawal/drop
outs’ (n = 28) were those who dropped out or were discon-
tinued from the injectable medications before 12 months
(various reasons: e.g., attempted to divert the study medi-
cations, violent behaviour, etc.). The primary outcomes for
the present analyses were days of illicit heroin use and re-
tention to treatment at 12 and 24-months follow-up.
Baseline characteristics were compared between the
withdrawal, involuntary and voluntary transition groups
using analysis of variance for continuous variables and
chi-square tests for categorical variables. At 12 and
24-months follow-up, the overall mean differences for
the EuropASI, MAP and EQ5D scores were compared
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comparisons were done using t-test for variables with
the overall p-value of less than 0.05 in the analysis of
variance. Multivariate regression models were also used
to analyse each of the primary outcomes at 12 and
24- months for the voluntary and involuntary transition
groups: 1) multivariate logistic regression models for re-
tention; and 2) multivariate linear regression models for
days of illicit heroin use. All regression models adjusted
for baseline characteristics, including age, gender, ethni-
city, chronic medical problems, years injecting drugs,
prior 30 days of illicit heroin use, prior 30 days of illegal
activities, and EuropASI-family sub-scale score. Finally,
we also included an intention to treat analysis of the
primary outcomes by the injectable and oral arms of
NAOMI. There were no missing data at 24-months for
retention. A multiple imputation technique was used forTable 1 Baseline characteristics for each transition group
Variable at baseline Injectable DAM or HDM (N = 139
Withdraw/drop out (N = 28)
Agea 39.7 ± 7.6
Female 9 (32.1%)
Aboriginal 9 (39.1%)
Chronic medical problem 19 (67.9%)
Previous MMT attempts 3.4 ± 1.7
Injecting drugsa 16.7 ± 7.9
Heroin use prior monthb 27.7 ± 5.2
Cocaine use prior monthb 20.8 ± 11.7
Illegal activities prior monthb, c 19.68 ± 11.43
Injecting prior monthb 16.71 ± 7.88
EuropASI-Drugd 0.57 ± 0.14
EuropASI-Legald 0.45 ± 0.18
EuropASI-Medicald 0.43 ± 0.33
EuropASI-Econd 0.88 ± 0.29
EuropASI-Job Satisfactiond 0.19 ± 0.26
EuropASI-Familyd, e 0.11 ± 0.14
EuropASI-Sociald 0.16 ± 0.22
EuropASI-Psychiatricd 0.24 ± 0.19
EQ5D (US weight)f 0.68 ± 0.21
EQ5D (UK weight)g 0.56 ± 0.31
MAP-Physicalh 17.64 ± 7.54
MAP-Psychologicalh 15.5 ± 8.57
Numbers are: Mean ± standard deviation or N (%).
(a)Years.
(b)Days.
(c)Analysis of variance; F-test = 4.00, df = 2, 136, p-value = 0.021.
(d)EuropASI (European version of the Addiction Severity Index); sub-scale scores ran
(e)Analysis of variance; F-test = 3.73, df = 2, 136, p-value = 0.026.
(f)EQ5D (Euroquol) US weights: Scores range from −0.11 to 1; higher scores are indi
(g)EQ5D (Euroquol) UK weights: Scores range from −0.594 to 1; higher scores are ind
(h)MAP (Maudsley Addiction Profile). Scores range from 0 to 40; higher scores are inmissing data and the adjusted degrees of freedom was
used for inference [19]. Data were analyzed using SAS®
(version 9.3) [20].
Findings
Table 1 summarizes group characteristics at baseline.
Compared to the involuntary transition group, there
were less women and Aboriginal participants in the vol-
untary transition group. This group was also younger
and had been injecting drugs for fewer years. However,
statistically significant differences between groups were
not observed for these variables, only for prior month
days of illegal activities and the EuropASI Family sub-
scale score reached statistical significance.
Table 2 shows retention and illicit heroin use for the vol-
untary and involuntary transition groups at 24 months. A
higher proportion of voluntarily transitioning participants)
Involuntary transition (N = 95) Voluntary transition (N = 16)
40.4 ± 7.9 37.6 ± 7.6
37 (38.9%) 4 (25.0%)
22 (29.3%) 1 (12.5%)
51 (53.7%) 7 (43.8%)
3.1 ± 1.8 2.8 ± 1.0
16.9 ± 10.2 14.9 ± 8.0
26.3 ± 8.2 26.4 ± 7.0
15.3 ± 12.6 14.9 ± 12.0
14.60 ± 12.68 8.94 ± 11.66
16.91 ± 10.23 14.88 ± 8.02
0.52 ± 0.14 0.55 ± 0.18
0.36 ± 0.26 0.27 ± 0.28
0.34 ± 0.35 0.41 ± 0.35
0.92 ± 0.23 0.83 ± 0.32
0.26 ± 0.33 0.27 ± 0.34
0.08 ± 0.19 0.22 ± 0.26
0.10 ± 0.18 0.17 ± 0.23
0.19 ± 0.21 0.26 ± 0.25
0.72 ± 0.2 0.71 ± 0.22
0.62 ± 0.31 0.61 ± 0.34
14.74 ± 7.35 15.44 ± 9.65
13.87 ± 7.78 14.81 ± 11.26
ge from 0 to 1; higher scores are indicative of more severe problems.
cative of better health status.
icative of better health status.
dicative of more symptoms.
Table 2 Retention and illicit heroin use for voluntary compared to involuntary transition groups
Outcome Voluntary groupa (n = 16) Involuntary groupa (n = 95) Voluntary vs Involuntary P Value
Adj. odds ratio (95% CI)
Retention
12 months 16 (100%) 95 (100%) - -
24 monthsc 14 (87.5%) 53 (55.8%) 5.55 (1.11, 27.81) 0.037e
Adj. mean difference (95% CI)
Illicit heroin use
12 monthsd 5.66 (1.35, 9.96) 2.68 (1.45, 3.92) 4.02 (0.31, 7.73) 0.034f
24 monthsc 2.55 (0, 8.35) 10.61 (8.18, 13.04) −5.58 (−11.62, 0.47) 0.070g
(a)Numbers are: Mean (95% Confidence Interval) or N (%).
(b)Models adjusted for baseline characteristics: age, gender, ethnicity, chronic medical problem, years injecting drugs, days of heroin use, days of illegal activities,
European addiction severity index - family sub-scale score.
(c)Adjusted odds ratio from the logistic regression model; not tested at 12 months.
(d)Adjusted mean difference from the linear regression model.
(e)Wald chi-square test, chi-square value = 4.33, df = 1.
(f)t-test, t-value = 2.16, adjusted degrees of freedom for multiple imputation = 76.6.
(g)t-test, t-value = −1.83, adjusted degrees of freedom for multiple imputation = 97.4
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group. Results from the multivariate logistic regression
model revealed that the voluntary transition group had
5.55 (95% CI = 1.11, 27.81; Chi-square = 4.33, df = 1,
p-value = 0.037) times the adjusted odds of retention at
24-months compared to the involuntary transition group.
Figure 1 illustrates the trajectory of illicit heroin use
over the 24-month study period. All groups reduced
their use of illicit heroin from baseline to 24-months.
From Table 2 it is also evident that the mean prior
30 days of illicit heroin use was higher for the involun-
tary compared to the voluntary transition group atFigure 1 Days of illicit heroin use from baseline to 24-months follow-24-months. The voluntary transition group had an
unadjusted mean difference of 8.06 (95% CI = −14.35,
−1.76; t-value = −2.53, adjusted df = 104.1, p-value =
0.013) days less of illicit heroin use in the prior 30 days
than the involuntary transition group. The mean differ-
ence in days of illicit heroin use between the voluntary
and involuntary transition groups at 24-months in the
adjusted model was −5.58 days (95% CI = −11.62, 0.47;
t-value = −1.83, df = 97.4, p-value = 0.07). Aside from
illicit heroin use and retention to treatment, the volun-
tary and involuntary transition groups were similar
in physical and psychological health and psychosocialup for voluntary, involuntary and oral treatment groups.
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untary transition group had a higher EuropASI- Social
functioning score compared to the involuntary transition
group (t-value = 2.14, adjusted df = 98.3, p-value = 0.034).
Table 3 displays ITT analysis of retention and illicit
heroin use by randomization arm at 12 and 24-months.
At 24 months the oral and injectable groups did not
statistically differ in either retention or illicit heroin
use. Days of illicit heroin use in the injectable group
was 9.78 mean days (95% CI = 7.71, 11.85) and for those
randomized to oral methadone was 11.48 mean days (95%
CI = 9.1, 13.87). Retention rates were 77 (55.4%) and 60
(56.6%) for the injectable and oral group respectively.
Discussion
The present analysis indicates that among individuals
eligible for 12-months of treatment with injectable di-
acetylmorphine or hydromorphone in a clinical trial, a
small sub-group of participants voluntarily transitioned
from injection medication to oral methadone during the
study. At the 24-month follow-up evaluation, these par-
ticipants had higher retention to addiction treatment
and fewer days of illicit heroin use in the prior 30 days,
when compared to participants whose injection treat-
ment was discontinued at 12-months due to the end of
the clinical trial.
In NAOMI, the 12-month treatment endpoint was not
mandated clinically but was due to the finite nature of
the clinical trial. Individuals in NAOMI had an average
of 16 years of prior heroin use, a history of MMT
attempts and no MMT in the 6-months prior study
inclusion, thus it is not surprising that the majority
randomized to injectable medications remained on this
treatment for the allocated treatment and transition
period. It is noteworthy that a group of participants vol-
untarily transitioned to methadone, which they hadTable 3 Retention and illicit heroin use by randomization arm
Outcome Injectablec (n = 139) Oral c (
Retentiona
12 months 123 (88.5%) 60 (5
24 months 77 (55.4%) 60 (5
Illicit heroin useb
12 months 5.23 (3.43, 7.04) 11.99 (9.
24 months 9.78 (7.71, 11.85) 11.48 (9
All analysis are intention to treat.
(a)No missing data.
(b)With multiple imputation.
(c)Numbers are: Mean (95% Confidence Interval) or N (%).
(d)Chi-square test (chi-square value = 32.25, df = 1).
(e)Chi-square test (chi-square value = 0.04, df = 1).
(f)t-test, t-value = −4.87, adjusted degrees of freedom for multiple imputation = 240.
(g)t-test, t-value = −1.06, adjusted degrees of freedom for multiple imputation = 159previously rejected. It could be suggested that treatment
with injectable diacetylmorphine provided them with an
opportunity to stabilize and the participants opted to
transition to oral methadone.
NAOMI was the only clinical trial with injectable di-
acetylmorphine that was unable to provide this treat-
ment beyond the 12 month period due to logistical,
financial and political reasons [12,21]. Despite differ-
ences in design and policies in place among studies, it is
noteworthy that among those who discontinued treat-
ment with diacetylmorphine in NAOMI (n = 44), volun-
tary transition rates to other treatments (primarily oral
methadone) is similar to other contexts. For example, in
the German study, among those who discontinued treat-
ment, 36% of participants receiving treatment with di-
acetylmorphine voluntarily switched to other treatments,
27% to oral methadone and 9% to abstinence oriented
treatment [8]. In the Swiss program, 2005 to 2010 yearly
transition rates to oral methadone, as a reason to leave
the program, have ranged from 35% to more than 45%
among those discontinuing injectable diacetylmorphine
[9]. The Swiss transition rates to other treatments de-
scribed above do not account for those who were with-
drawn or dropped out from diacetylmorphine treatment
for other reasons (e.g., due to behavioral issues or mov-
ing away) and started MMT.
The involuntary transition group, despite adjusting for
baseline differences and being retained for the 12-month
treatment period, experienced an increase in their illicit
heroin use at 24-months. Moreover, intention to treat
analysis showed that although at 12 months the inject-
able arm had significantly higher retention and less illicit
heroin use than the oral arm, at 24 months this differ-
ence disappeared. This evidence suggests that with con-
tinued provision of injectable medications, participants
could have sustained the achieved positive outcomes andn = 106) Injectable vs Oral P Value
Relative risk (95% CI)
6.6%) 1.56 (1.31, 1.87) <0.0001d
6.6%) 0.98 (0.78, 1.22) 0.851e
Mean difference (95% CI)
91, 14.07) −6.76 (−9.49, −4.02) <0.0001f
.1, 13.87) −1.7 (−4.87, 1.47) 0.291g
6.
.3.
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treatments or abstinence. The German study, for ex-
ample, found that some psychosocial outcomes might take
as long as 4 years of treatment with injectable diacetyl-
morphine before reaching marked improvements [22].
Limitations of the NAOMI trial have been discussed
elsewhere [11,12]. NAOMI was not designed to deter-
mine the outcomes of participants voluntarily transition-
ing to oral methadone; thus, the small sample sizes of
the voluntary and involuntary transition groups impacts
the statistical power of the present analysis and its con-
clusions. Motivating factors for transitioning from inject-
able treatments were not part of questionnaire data.
Although, a qualitative sub-study [23] conducted with
participants in both arms found that participants receiv-
ing injectable treatments were disappointed with the
study ending. These participants discussed that the 12-
month period was sufficient to experience many initial
benefits but not long enough for those benefits to be
fully sustained. Nevertheless, this study allows us to ex-
plore outcomes of those who voluntarily transitioned to
oral MMT in the context of the Canadian trial.
These studies and our data underline the critical import-
ance of patient-centered decision making. If injectable
treatments were continued beyond the end of the study,
some participants may have sustained the achieved im-
provements and some voluntarily transitioned to other al-
ternatives in time. To be able to provide patient-centered
care, an addiction treatment system should offer diversi-
fied opioid options for substitution treatment that would
grant patients and doctors to choose the most effective
treatment at a given time, case by case.
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